Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
about
Interaction between Glucose and Lipid Metabolism: More than Diabetic DyslipidemiaHDL and glucose metabolism: current evidence and therapeutic potentialCardioprotective functions of HDLsMendelian Randomization and Type 2 DiabetesIntegrative genomics reveals novel molecular pathways and gene networks for coronary artery disease.Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach.Skeletal muscle insulin resistance associated with cholesterol-induced activation of macrophages is prevented by high density lipoprotein.Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis.Cholesteryl Ester Transfer Protein (CETP) expression does not affect glucose homeostasis and insulin secretion: studies in human CETP transgenic miceReverse Engineering and Evaluation of Prediction Models for Progression to Type 2 Diabetes: An Application of Machine Learning Using Electronic Health Records.Assessment of established HDL-C loci for association with HDL-C levels and type 2 diabetes in Pima IndiansThe effect of cholesteryl ester transfer protein on pancreatic beta cell dysfunction in miceClinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsThe role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities.Impact of Diabetes Mellitus.High density lipoprotein: a therapeutic target in type 2 diabetes.Cholesteryl ester transfer protein protects against insulin resistance in obese female mice.High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammationNew horizons for cholesterol ester transfer protein inhibitors.The emerging role of HDL in glucose metabolism.New lipid-lowering drugs: an update.Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?High-density lipoprotein, beta cells, and diabetes .Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.HDL cholesterol: reappraisal of its clinical relevance.CETP Inhibition in CVD Prevention: an Actual Appraisal.Cholesteryl ester transfer protein inhibitors: challenges and perspectives.Pharmacological management of diabetic dyslipidemia.Low Levels of High-Density Lipoprotein Cholesterol Do Not Predict the Incidence of Type 2 Diabetes in an Iranian High-Risk Population: The Isfahan Diabetes Prevention Study.HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial.Killing two birds with one stone, maybe: CETP inhibition increases both high-density lipoprotein levels and insulin secretion.In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis.Trials and Tribulations of CETP Inhibitors.Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?In vivo PET imaging with [(18)F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes.[Clinical importance of HDL cholesterol].
P2860
Q26777184-4B7E8744-E9D0-4824-A980-48CC7E80B6F3Q26996502-88D97C47-84B4-4D5C-AE2F-FE3D20A308DFQ27000421-6F2783C9-F557-45DB-A0F0-8F49C69BB907Q28072229-FFE23ACA-40E9-4A10-8E4A-B362C73E4E4DQ33916015-04A1A822-2CF3-4317-9A17-2194CDD5EF0DQ34253290-97D74921-A955-4633-9B81-0AB19477DBE0Q34507683-5A4E1215-7F50-4F2C-A56F-18AD417B4FFBQ34599077-F1C80964-A370-4FB7-BA8D-4F9525226D5CQ35207915-E83CD65D-29CE-4269-A460-87B7AFB779FAQ36457876-996351AB-DE27-4F50-B39D-5278C3E4FB62Q36535983-E772CC43-80C4-4D59-9AC3-A0F7FD3771FDQ36552385-51E63A71-A540-4B58-B947-086E2DBEF613Q36679114-3CE8FF68-2F8E-4835-8BB1-040416F4F5DEQ37011769-0470F7AC-A8D2-4CA3-8363-B69F44D1B9C6Q37024780-F1AD32D7-4C0C-4080-BDC6-EB2C5491CEDDQ37149768-1780A92A-ACD3-4C81-8325-AA962DB6EF72Q37264429-D552F44D-7EAD-4E41-BAF3-E0E26B673260Q37372858-C7F120A5-6406-4A8A-A5BD-14C169E6553CQ37603213-8B87F9F3-545D-448F-902D-B245DE69AA46Q37956122-E65ACB0F-0223-4927-A269-6771794A76D4Q37978209-E6BB68F4-1A7E-4D6E-94AA-05B603D6C38FQ37984782-1677DE83-1A73-46B3-AB66-B200CD0697ECQ38039980-A8D119FF-A5FC-47E9-B3C0-15F7FB4166CFQ38067634-DB5629AD-5DBE-450C-B505-7AD6686FB547Q38218039-8787A409-8884-46DA-93AB-85D6A260349EQ38222135-BDDB3EBB-EE2A-48E8-B2AF-D7C1476ABC19Q38739884-7A4B4BD9-A13B-47B6-B215-97C90DC8862EQ38784639-9492050B-B04E-4322-923F-E0BCACD7CF66Q38832774-A04F8824-1175-46BE-8B88-001179BEAF26Q39015072-6BD37258-747A-46B1-973F-3AD8AF2CA435Q39067050-16BE2900-59C8-44BB-84C2-DC0D8C176FADQ42158972-17CD0149-BA36-4EF1-A751-DE941DAC4B2AQ42410902-07AB4669-CDEE-402A-A4EB-EAE8C4C08044Q45762096-1D277C73-AAE7-4970-8F42-4895C90A703BQ46562930-5567F055-E365-4EB4-BE08-F714E788983CQ47405486-BB56AEEA-F106-48BE-8D39-D6A867A14D28Q47669381-F28DACB1-4272-4D04-95BA-803AD4350C57Q47726362-3338CA08-5FF0-4AF6-BB39-F52C46ADC150Q48726745-C1083AC9-B995-4D9E-97F6-83F331CCDD89Q52813315-760CAAB8-B551-45ED-A725-1F29708B00EB
P2860
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Effect of torcetrapib on gluco ...... tic Events (ILLUMINATE) trial.
@en
type
label
Effect of torcetrapib on gluco ...... tic Events (ILLUMINATE) trial.
@en
prefLabel
Effect of torcetrapib on gluco ...... tic Events (ILLUMINATE) trial.
@en
P2093
P1433
P1476
Effect of torcetrapib on gluco ...... tic Events (ILLUMINATE) trial.
@en
P2093
Andrei Breazna
David D Waters
Jean-Claude Tardif
John J P Kastelein
Kerry-Anne Rye
Philip J Barter
S Matthijs Boekholdt
P304
P356
10.1161/CIRCULATIONAHA.111.018259
P407
P577
2011-07-18T00:00:00Z